RAD51B mutation	Prostate Cancer	RAD51B mutation	Prostate Cancer	olaparib Sensitive: A2 - Guideline olaparib Sensitive : A2	olaparib Sensitive: A2 - Guideline olaparib Sensitive : A2
RAD51B mutation	Ovarian Cancer	RAD51B mutation	Ovarian Cancer	olaparib Sensitive: B - Late Trials olaparib Sensitive : B	olaparib Sensitive: B - Late Trials olaparib Sensitive : B
RAD51B mutation	Small Cell Lung Cancer	RAD51B mutation	Small Cell Lung Cancer	olaparib Sensitive: C2 – Inclusion Criteria olaparib Sensitive : C2	olaparib Sensitive: C2 – Inclusion Criteria olaparib Sensitive : C2
RAD51B mutation	HER2 Negative Breast Cancer	RAD51B mutation	HER2 Negative Breast Cancer	durvalumab Sensitive: C2 – Inclusion Criteria durvalumab Sensitive : C2	durvalumab Sensitive: C2 – Inclusion Criteria durvalumab Sensitive : C2
RAD51B promoter methylation	Non Small Cell Lung Cancer	RAD51B promoter methylation	Non Small Cell Lung Cancer	Immunotherapy Sensitive: C3 – Early Trials Immunotherapy Sensitive : C3	Immunotherapy Sensitive: C3 – Early Trials Immunotherapy Sensitive : C3
RAD51B promoter methylation + PD-L1 expression	Non Small Cell Lung Cancer	RAD51B promoter methylation + PD-L1 expression	Non Small Cell Lung Cancer	pembrolizumab Sensitive: C3 – Early Trials pembrolizumab Sensitive : C3	pembrolizumab Sensitive: C3 – Early Trials pembrolizumab Sensitive : C3
RAD51B promoter methylation	Non Small Cell Lung Cancer	RAD51B promoter methylation	Non Small Cell Lung Cancer	nivolumab Sensitive: C3 – Early Trials nivolumab Sensitive : C3	nivolumab Sensitive: C3 – Early Trials nivolumab Sensitive : C3
RAD51B promoter methylation + PD-L1 expression	Non Small Cell Lung Cancer	RAD51B promoter methylation + PD-L1 expression	Non Small Cell Lung Cancer	nivolumab Sensitive: C3 – Early Trials nivolumab Sensitive : C3	nivolumab Sensitive: C3 – Early Trials nivolumab Sensitive : C3
RAD51B promoter methylation	Non Small Cell Lung Cancer	RAD51B promoter methylation	Non Small Cell Lung Cancer	pembrolizumab Sensitive: C3 – Early Trials pembrolizumab Sensitive : C3	pembrolizumab Sensitive: C3 – Early Trials pembrolizumab Sensitive : C3
RAD51B deletion	Uterine Leiomyosarcoma	RAD51B deletion	Uterine Leiomyosarcoma	olaparib Sensitive: C3 – Early Trials olaparib Sensitive : C3	olaparib Sensitive: C3 – Early Trials olaparib Sensitive : C3
BRCA1 mutation + RAD51B deletion	Triple Negative Breast Cancer	BRCA1 mutation + RAD51B deletion	Triple Negative Breast Cancer	carboplatin Sensitive: C4 – Case Studies carboplatin Sensitive : C4	carboplatin Sensitive: C4 – Case Studies carboplatin Sensitive : C4

RAD51B (RAD51 Paralog B)

Associations(11)

Associations
(11)